Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

v3.22.2
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Beginning balance, value at Mar. 31, 2020 $ 2,000 $ 186,559,000 $ (175,327,000) $ (5,610,000) $ 5,624,000
Beginning balance, shares at Mar. 31, 2020 1.55 1,777,483        
Shares issued in connection with exercise of stock options 511,000 511,000
Shares issued in connection with exercise of stock options, shares   93,301        
Shares issued in connection with vesting of restricted stock
Shares issued in connection with vesting of restricted stock, shares   3,919        
Shares issued in connection with exercise of common stock warrants 1,776,000 1,776,000
Shares issued in connection with exercise of common stock warrants, shares   200,984        
Shares issued with conversion of C shares
Shares issued with conversion of C shares, shares (1.55) 17,222        
Employee stock-based compensation expense 332,000 332,000
Stock based compensation related to issuance of common stock restricted stock grants 39,000 39,000
Foreign currency translation adjustment   1,031,000 1,031,000
Net loss (3,950,000) (3,950,000)
Ending balance, value at Mar. 31, 2021 $ 2,000 189,217,000 (179,277,000) (4,579,000) 5,363,000
Ending balance, shares at Mar. 31, 2021 2,092,909        
Shares issued in connection with ATM, net of transaction costs 7,554,000 7,554,000
Shares issued in connection with ATM, net of transaction costs, shares   950,100        
Shares issued in connection with exercise of stock options 193,000 193,000
Shares issued in connection with exercise of stock options, shares   44,042        
Shares issued in connection with exercise of common stock warrants 24,000 24,000
Shares issued in connection with exercise of common stock warrants, shares   12,290        
Employee stock-based compensation expense 372,000 372,000
Stock based compensation related to issuance of common stock restricted stock grants 10,000 10,000
Stock based compensation related to common stock restricted stock grants, shares   1,596        
Foreign currency translation adjustment   267,000 267,000
Net loss (5,086,000) (5,086,000)
Ending balance, value at Mar. 31, 2022 $ 2,000 $ 197,370,000 $ (184,363,000) $ (4,312,000) $ 8,697,000
Ending balance, shares at Mar. 31, 2022 3,100,937